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Abstract
This chapter examines associations between psychotropic medications and 
mortality in long-term care home (LTCH) settings. We report new findings with 
census-level data from all new admissions to long-term care homes in the province 
of Ontario, Canada (i.e., 20,414 new residents). The data include three linked sets 
that indicate mortality during the financial years 2010–2011 and 2011–2012. One 
dataset, the Resident Assessment Instrument 2.0 (RAI 2.0), provides information 
on demographics, functional capability, clinical conditions, clinical diagnoses, 
mortality risk, and psychotropic medications. The latter include antipsychotics, 
antidepressants, analgesics, anxiolytics, and hypnotics. Administration of the RAI 
2.0 occurs at resident intake, at quarterly intervals and annually. New analyses 
reported here examine predictors of daily and pro re nata (i.e., PRN or “as needed”) 
prescriptions of psychotropic medications. However, the most important analyses 
concern predictors of mortality within intervals of up to 90 days from the final RAI 
2.0 assessment. After control for confounding variables, the findings indicate (1) 
attenuated mortality with daily prescription of frequently prescribed psychotropics 
(i.e., antipsychotics, antidepressants, and analgesics), (2) augmented mortality 
with PRN prescriptions for each type of psychotropic medication, and (3) evidence 
that PRN prescribing overturns beneficial effects of daily prescriptions, whereas 
the latter reduces the deleterious effects of PRN prescribing.
Keywords: mortality, medication, psychotropic, antipsychotic, analgesic, 
antidepressant, anxiolytic, hypnotic, aging, elderly, gerontology, long-term care, 
dementia
1. Introduction
This chapter illustrates a truism that pathways pursued in scientific investigation 
often deviate from linear trajectories. The research we report here evolved from 
concerns about ongoing practices in the continuing care of older people, a seren-
dipitous convergence of people with compatible research needs and desires, and 
totally unanticipated findings in need of further investigation. This section of the 
chapter traces the earlier stages of that progression.
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1.1  Concern about associations of antipsychotic medication and mortality in 
older people
The research that follows evolved from participation by the lead author in 
unpublished work in the late 1990s commissioned by the Canadian Institute for 
Health Information (CIHI). The purpose was to analyze early Canadian data on 
version two of the Minimum Data Set (MDS 2.0), which is the former name of the 
RAI 2.0. In 1996, this tool became mandated for use in all chronic care hospitals, 
now known as complex community care (CCC) facilities in the Canadian Province 
of Ontario. The residents of these facilities are mainly older people in receipt of 
continuing care and/or rehabilitation associated with disabling chronic illness.
The findings from that work that was most troubling included high frequencies 
of physical restraint and chemical management in Canadian facilities compared to 
findings with the same tool in other countries. Although Canadian physical restraint 
levels lessened in frequency since that time, such is not the case for chemical man-
agement. Hence the enduring interest in chemical management by these authors.
The purpose of chemical management is to address symptoms that fall under the 
umbrella of behavioral and psychological symptoms of dementia (BPSD). The 
definition of the latter at a 1996 Consensus Conference of the International 
Psychogeriatric Association (IPA) is as follows: “symptoms of disturbed perception, 
thought content, mood or behavior that frequently occur in patients with dementia” 
[1]. The behavioral symptoms include physical aggression, loud vocalization, rest-
lessness, agitation, and wandering. The psychological symptoms include anxiety, 
depressive mood, hallucinations, and delusions.
Current estimates suggest that over half the patients with dementia are at risk 
to such symptoms, which typically arise during the middle or later stages of the 
disease. Chemical management may include analgesics to lessen pain and discom-
fort, along with antidepressants, anti-anxiety medication and antipsychotics, all 
of which address behavioral and psychological symptoms [2]. The most frequent 
concerns about chemical management relate to antipsychotic medication. These are 
drugs first developed for the treatment of psychosis [3]. Presently, antipsychotic 
drugs fall within two categories. Typical antipsychotics include those initially 
developed to treat psychosis, while atypical antipsychotics were developed later to 
reduce adverse side effects of the former.
Concerns about harmful effects of antipsychotics in dementia patients are 
legitimate. The adverse effects of these drugs include high rates of cardiovascular 
events, cardiac arrhythmias, cerebrovascular events, cognitive decline, extrapyra-
midal symptoms, pneumonia, falls and fractures, and others [4]. However, the most 
serious concern is an elevated risk of mortality. Notice of such concerns began early 
this millennium with evidence that these adverse effects were over and above those 
associated with old age, an underlying dementia, and behavioral and psychological 
symptoms that might precipitate the use of antipsychotics [5].
In 2002, the manufacturer of a typical antipsychotic medication warned of an 
increased risk of adverse cardiovascular events [5]. Subsequently, the US Federal 
Food and Drug Administration (FDA) required “black box” warnings about the use 
of atypical antipsychotics (in 2005) and typical antipsychotics (in 2008). The warn-
ing states: “WARNING: Elderly patients with dementia-related psychosis treated 
with antipsychotic drugs are at an increased risk of death.” Health authorities in 
other countries subsequently expressed similar concerns.
Conclusions from the most recent and most extensive meta-analysis of stud-
ies that relate the use antipsychotic medication to the mortality of elderly people 
[6] are as follows. Mortality risk with antipsychotic medication (1) is twice 
that of people without such prescription, (2) comparable between typical and 
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atypical antipsychotics, (3) highest during the initial half-year of use, (4) higher 
at higher dosage, and (5) comparable between people with or without diagnosed 
dementia. One interpretation of these five points is that people with more severe 
dementia-related psychosis are at greater risk of mortality, with that risk lessen-
ing 6 months after they begin that course of medication. However, findings from 
placebo-controlled trials indicate antipsychotic use is associated with an increase in 
mortality above and beyond the baseline dementia symptoms. The authors of this 
meta-analysis also recommended a restricted use of antipsychotic medication with 
older people and encouraged the deployment of de-prescribing practices.
Final thoughts by those authors concur with comments made earlier by authors 
of this chapter [7]. Ralph and Espinet [6] anticipate greater cultural disapproval 
about the sedation of older people through antipsychotic, anxiolytic, and hypnotic 
medications. They envision attitudinal changes within the health and legal profes-
sions to consider such practices examples of systemic elder abuse that requires legal 
reform. A current drive toward the de-prescribing of antipsychotic medication to 
elderly people is consistent with these beliefs [8].
1.2 Preliminary study of antipsychotic medication and mortality in older people
When Sarah Worobetz, a doctoral student at Lakehead University, wanted to research 
relationships between antipsychotic medication and mortality in older people, after 
control for a wide range of variables we describe subsequently, faculty members Michael 
Stones and Peter Brink were happy to oblige. These researchers had a working familiarity 
with the RAI 2.0. They hoped to obtain census level data, with linkages to other mortality 
relevant datasets, to provide Sarah with the means to conduct her research. Peter Brink 
successfully submitted a proposal to CIHI for access to access these data.
The RAI 2.0 is a standardized assessment tool used routinely in LTCH and CCC 
facilities in Ontario and other settings across the world. The tool contains over 350 
items relevant to medical diagnoses; physical, cognitive, social, and emotional 
functioning; and treatment categories that include medication use. It also indexes 
mortality within the relevant facilities. The trained health care professionals respon-
sible for RAI 2.0 assessments obtain that information from multiple sources, such 
as direct observation, medical records, and communication with family members 
and other health care professionals. Objective scales on the RAI 2.0 consist of sets of 
items selected for relevance to a given construct. Evaluation of such scales may be 
against “gold standard” measures of the constructs (e.g., measures of activities of 
daily living, cognitive status, depression, aggression, and pain) or relevant outcomes 
(e.g., mortality risk). From a measurement perspective, previous findings on data 
quality and the reliability and validity of RAI 2.0 measures are positive [8–10].
The antipsychotic medication item on the RAI 2.0 falls within a psychotropic 
category that also contains items on antidepressant, analgesic, anxiolytic, and 
hypnotic medications. The wording of each of these items asks for the number of 
days during the past week that the resident received the medication. This form 
of measurement differs from that common to previous studies of psychotropic 
medication and mortality, which invariably report specific medications and dosages 
but not frequency of medication use.
The other databases provided by CIHI are the Discharge Abstract Database (DAD) 
and the National Ambulatory Care Reporting System (NACRS). The DAD contains 
demographic, administrative, and clinical data for hospital discharges (inpatient 
acute, chronic, and rehabilitation) and day surgeries. The NACRS contains data for 
hospital-based and community-based emergency and ambulatory care (e.g., day 
surgery and outpatient clinics). Both datasets contain mortality data pertaining to 
their respective contexts. CIHI encrypted the personal and facility identifiers across 
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datasets to ensure anonymity of residents. Brink merged these three datasets for pur-
poses of analysis. Consequently, the merged file contains mortality data both within 
LTCH and CCC facilities and for those discharged to other health care settings.
The dataset analyzed by Worobetz includes all admission, quarterly and annual 
RAI 2.0 assessment for residents aged over 65 years in all LTCH and CCC facilities in 
Ontario during the financial years 2010–2011 and 2011–2012. The data are from 102,658 
residents of approximately 760 facilities with a mean of 5.83 assessments per resident. 
Approximately 70% of residents are female and 30% male, with a mean age over all 
assessments of approximately 84 years. Approximately 86% of residents live in LTCH 
and 14% in CCC facilities. The mean length of stay prior to the first assessment was 
approximately 20 months, with the age at entry approximately 82 years. The distribu-
tion of antipsychotic prescriptions shows that approximately 69% of residents are with-
out medication, 29% have daily prescriptions, and 2% have prescriptions of 1–6 days 
per week, which for purposes of this research we describe as PRN prescriptions. The 
total mortality rate during the 2-year period of data collection is approximately 32%.
The initial findings by Worobetz on relationships between mortality and type of 
antipsychotic prescription came as a big surprise. Her analysis by generalized linear 
mixed modeling (GLMM) appointed LTCH as a random effect variable (i.e., inde-
pendent entities) with residents clustered (i.e., showing covariation) within their 
respective facilities. Such modeling is appropriate because of differences among 
facilities with respect to admission criteria, population size, staffing levels, types 
of programming, treatment protocols, etc., with localized interpersonal exchanges 
within facilities that foster covariation among residents. Compared to residents 
with no prescription for antipsychotic medication, her findings show attenuated 
mortality for those with daily prescription, but augmented mortality for those with 
PRN prescription. A possible interpretation is that these findings are consistent 
with earlier evidence of a protective effect of antipsychotics after 6 months but 
an increased mortality risk for residents prescribed antipsychotics on a PRN basis 
because they began to exhibit relevant symptoms.
Subsequent GLMM analyses by Worobetz included all residents, only those from 
LTCH, only those from CCC, new admissions, residents with dementia, and combi-
nations of the preceding. The fixed effect variables in such analyses included not just 
prescriptions for antipsychotic medication but multivariate control for confounding 
variables such as demographics, scores on RAI 2.0 scales (e.g., activity limitation, 
cognitive status, aggression, depression, and mortality risk), temporal changes on 
those scales, and medical diagnoses (e.g., cancer, dementia, maniac depression, and 
schizophrenia [11]). The findings from all these analyses consistently show highest 
mortality among residents with PRN prescriptions on the final assessment.
1.3 Studies of other psychotropic medications and mortality in older people
The preceding findings provide reasons to broaden the scope of investigation 
to encompass mortality in relation to prescriptions of other types of psychotropic 
medication. We begin this section with brief discussion of prescribing practices and 
mortality associated with analgesics, antidepressants, anxiolytics and hypnotics, 
which in the RAI 2.0 fall within an item-set of psychotropic medications. Then fol-
lows discussion of problems associated with PRN prescribing practices. Finally, we 
report findings from separate analyses of mortality against these types of psycho-
tropic medications.
Prescribing practices with analgesics show the following trends. Although rates 
for PRN prescription in elderly care services are generally low, some reports indicate 
highest levels for analgesics [12]. Worldwide, scheduled rates for analgesic use (that 
include acetaminophen and opioids) in LTCH show a historical increase, whereas 
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rates for scheduled plus PRN rates show no such increase [13]. Recent findings from 
the Czech Republic suggest that a large proportion of LTCH residents with pain 
receive no analgesic medication and a moderate proportion of those that receive 
analgesic medication continue to report pain. These findings of analgesic under-
prescription are consistent with those from North America and elsewhere in Europe. 
The lowest frequency of reported pain and lowest prevalence of analgesic adminis-
tration are for residents with moderate-to-severe dementia [14], which suggests this 
group’s susceptibility to under-detection and under-prescribing of this medication.
Anti-depressant medications find frequent use in older people, with average 
prevalence rates of approximately 25% [15, 16]. Recent evidence suggests no associa-
tion between antidepressant prescriptions and augmented risk of all-cause mortality 
[17, 18]. However, best practice guidelines recommend caution when prescribing 
because low adherence may increase risks of fatal cardiovascular and cerebrovascu-
lar injuries [19]. On the other hand, high adherence appears to lower mortality risk 
[20]. The findings give rise to hypotheses that intermittent use of antidepressants 
(e.g., comparable to PRN prescribing) has unfavorable implications for mortality 
whereas regular use (e.g., associated with daily prescription) has favorable implica-
tions. However, we will discuss other interpretations later in the chapter.
A recent review suggests that benzodiazepines are the most frequently pre-
scribed anxiolytic medications for geriatric anxiety [21]. However, consensus is low 
about whether anxiolytic and hypnotic medications have unfavorable implications 
for mortality risk amongst older adults [22]. On the other hand, a large-scale retro-
spective cohort study of patients in UK primary care concluded that anxiolytic and 
hypnotic drugs were associated with significantly increased risk of mortality over a 
7-year period, after adjusting for a range of potential confounders [23].
A number of studies and reviews examined PRN prescription in psychiatric and 
LTCH settings [24–27]. Summary findings indicate higher PRN use for residents with 
lower care needs, frequent use alongside regularly scheduled medications, and recent 
entry into a facility. Contextual factors also have a strong influence on PRN prescrib-
ing. These include general levels of activity and disturbance on the ward, staffing 
level, perceived competence of staff, and familiarity of the staff with residents. The 
reports also indicate frequent omissions and errors in records of PRN usage. Findings 
that relate mortality to PRN usage appear to be absent in the literature.
Following the thesis research by Worobetz, subsequent analyses of the same dataset 
examined relationships of mortality to prescriptions of anesthetics (Jason Randle), 
antidepressants (Carlina Marchese and Shauna Fossum), anxiolytics (Michael Stones), 
and hypnotics (Dane Ostrom). We describe the sampling procedure in the following 
section. The main findings show significantly higher mortality with PRN prescriptions 
for each type of psychotropic medication compared with daily or null prescription. 
These findings persist even after statistical control of relevant confounding variables. 
They provide the impetus for the new analyses that follow.
2.  New analyses on relationships between psychotropic medication  
and mortality
We try here to expand the scope and level of precision beyond those present 
in previous analyses, each of which examined associations of mortality with a 
single psychotropic medication. First, we analyze the effects on mortality of all the 
psychotropic prescriptions within a series of multivariate analyses that includes the 
psychotropic medications. Second, we introduce a verified measure of mortality 
risk into the array of control variables. Third, we examine intervals for mortality 
of 90 days from the final RAI 2.0 assessment (i.e., the scheduled date of the next 
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assessment) and shorter periods within that interval. Fourth, we examine predic-
tors of daily and PRN prescriptions of psychotropic medications. Fifth, we examine 
the effects on mortality for residents receiving only daily, only PRN, or both daily 
and PRN prescriptions of psychotropic medication.
2.1 Methods
Section 1.2 described the three datasets linked and encrypted by CIHI. Here we 
report analyses that restrict data entry to (1) scheduled intake, quarterly and yearly 
assessments, (2) in LTCH settings, (3) for residents aged 65+ years, (4) with an 
intake assessment during the financial year 2010/2011, and (5) subsequent assess-
ments that do not exceed first yearly assessment (i.e., <13 months after the intake 
assessment). Consequently, the data enable computation of a census level 1-year 
incidence rate for mortality among LTCH residents aged 65 years and older.
The analyses that follow begin at a descriptive level and proceed to an inferential 
level. The latter analyses were performed using the SPSS 25 GLMM program. The 
target variables in different analyses include mortality within 90 days of the final 
assessment, time to mortality within that interval, and frequencies of daily and 
PRN prescriptions for psychotropic medication categories. The random variable in 
all analyses identifies the LTCH at intake assessment. Evidence of statistical signifi-
cance for the random variable would confirm that levels on the target variable differ 
across the LTCH spectrum.
The fixed effects in different analyses include the following RAI 2.0 measures: 
demographics (gender, age at assessment); scales (Activities of Daily Living 
Hierarchy, Cognitive Performance Scale, Depression Rating Scale, Aggressive 
Behavior Scale, Pain Scale and the Changes in Health, End-Stage Disease, and 
Symptoms and Signs Scale); diagnoses (insomnia and dementia), and medications 
(antipsychotic, antidepressant, analgesic, anxiolytic, and hypnotic). Convincing 
evidence from earlier and more recent publications [28] attest to good data quality 
and psychometric properties associated with RAI 2.0 measures.
2.2 Results
Here we describe the sample with respect to demographics, psychotropic medi-
cation use, and mortality. The sample of 20,414 residents of 631 LTCH includes 
approximately 38% admissions from inpatient acute care, 28% from a private home, 
13% from residential board and care, and 10% from home care. The remaining 11% of 
admissions are from residences with 24-hour nursing care, inpatient continuing care, 
inpatient rehabilitation, or inpatient psychiatry. The sample comprises 33.6% men and 
66.4% women. The age distribution for men has a mean of 83.03 years and standard 
deviation of 7.37 years, with respective estimates for women of 85.29 and 7.19 years.
Table 1 shows percentage frequencies for residents prescribed psychotropic 
medication during the week before the final assessment. Daily prescription is high-
est for analgesics followed by antidepressants followed by antipsychotics. More than 
half the residents use analgesics daily, nearly half use antidepressants daily, and 
approximately 30% receive daily antipsychotics. The frequency of PRN usage is low. 
The highest frequencies are 7.5% for analgesics and 3.3% for anxiolytics.
Frequencies of daily prescriptions for different types of psychotropic medica-
tion are as follows: 33.4% of residents receive one medication; 31.5% receive two 
medications; 17.6% use three or four (i.e., 3+) medications; and 17.4% of residents 
have no daily psychotropic medication. Frequencies for PRN prescriptions of 
psychotropic medication are as follows: 10.9% of residents use one medica-
tion; 1.6% use two or three (i.e., 2+) medications; and 87.5 of residents have no 
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psychotropic medication on a PRN basis. Frequencies for combinations of daily 
and PRN prescriptions are as follows: 74.6% of residents have only daily prescrip-
tions for psychotropic medications; 4.5% have only PRN prescriptions; 8.0% have 
both daily and PRN prescriptions; and 12.9% have no prescription. These findings 
indicate that about half the residents receive two or more psychotropic medica-
tions daily, 12.5% receive one or more on a PRN basis, and 8.0% have both daily 
and PRN prescriptions.
Probabilistic mortalities within 90 days of the final assessment are 18.1% overall, 
21.1% for males and 16.3% for females. The percentages of residents dying within 
different time periods after the final assessment are as follows: 2.2% mortality 
within 7 days after the final assessment, 6.1% within 8–30 days, and 9.8% within 
31–90 days. The proportion of residents with no mortality within 90 days is 82%.
2.2.1 Analysis of mortality’s association with prescriptions of psychotropic medications
The purpose is to evaluate whether findings from separate analyses of relation-
ships between mortality and types of psychotropic medication replicate in multi-
variate analysis that includes all such medications and potential confounders. The 
most significant findings from the earlier research indicate highest mortality with 
PRN prescription for each type of psychotropic medication. Replication in multi-
variate analysis would suggest that such relationships exist independently of any 
covariation in prescribing practices across types of medication.
The target variable in this analysis is mortality within 90 days of the final 
assessment, with 90 days being the time before the next scheduled assessment. The 
reference category for this variable is absence of mortality. The distribution of the 
target variable is binomial and related to a linear model by a complementary log-log 
link. SPSS 25 recommends such a linkage in survival analysis, where some observa-
tions have no termination event.
The fixed effects include demographic variables (i.e., men/women, age at the 
final assessment); measures of functional capability (i.e., Cognitive Performance 
Scale, Activities of Daily Living Hierarchy); and prescribed frequency of usage for 
each type of psychotropic medication (i.e., none, PRN, daily). The analysis accords 
with conventional GLMM practices that include centering of continuous measures 
on their grand mean and comparison of levels on a nominal variable with a refer-
ence category. For the present nominal measures, the respective reference categories 
are male gender and zero frequency of usage for a psychotropic medication.
Findings for the random variable in this and all subsequent analyses indicate 
significant differences (at p < 0.001) in levels of the target variable of mortality across 
facilities. The findings for fixed effects in Table 2 indicate lower mortality in women 
than men and higher mortality at older ages. Mortality also increases with activity 
Prescription of psychotropic medication
Medication type None (%) PRN (%) Daily (%)
Antipsychotic 69.2 1.4 29.4
Antidepressant 50.9 1.4 47.7
Analgesic 34.6 7.5 57.9
Anxiolytic 84.9 3.3 11.8
Hypnotic 93.7 0.7 5.6
Table 1. 
Percentage frequencies for usage of psychotropic medications.
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limitation, as indexed by higher scores on the activities of daily living scale. The findings 
for psychotropic medications show significantly lower mortality for daily antipsychotic 
and antidepressant prescription compared with no prescriptions. The findings for 
PRN prescriptions show significantly higher mortality for all types of psychotropic 
medication relative to no prescription and (in subsequent paired comparisons) daily 
prescription.
Figures 1–5 illustrate the magnitude of these findings, which are present in 
both men and women.
The findings from this analysis replicate in a multivariate context those from sepa-
rate analyses of each psychotropic medication. We conclude, therefore, that associa-
tions between PRN prescription and higher mortality are independent for each type 
of psychotropic medication. Compared to previous research, the findings of lower 
mortality with daily antipsychotic and antidepressant prescription are unusual for the 
former but not the latter. However, we have no reason to doubt their validity, based as 
they are on census level data from an entire province. It is possible that confounding 
factors that contribute to earlier reports of augmented mortality with antipsychotic 
medication include failures to distinguish daily from intermittent usage and to iden-
tify adherence to daily prescription regimens. The presence of either confound might 
overturn protective effects associated with antipsychotic medication.
Model term Odds ratio Sig. 95% confidence interval
Lower Upper
Intercept 0.21 0.000 0.19 0.23
Female 0.68 0.000 0.64 0.73
Male
Age at assessment 1.03 0.000 1.03 1.04
Activities of daily living 1.49 0.000 1.46 1.53
Cognitive performance 0.98 0.144 0.96 1.01
Daily antipsychotic 0.92 0.040 0.85 1.00
PRN antipsychotic 1.59 0.000 1.28 1.96
No antipsychotic
Daily antidepressant 0.78 0.000 0.72 0.83
PRN antidepressant 1.37 0.004 1.11 1.69
No antidepressant
Daily analgesic 0.98 0.555 0.91 1.05
PRN analgesic 1.72 0.000 1.53 1.93
No analgesic
Daily anxiolytic 0.99 0.899 0.89 1.11
PRN anxiolytic 1.40 0.000 1.20 1.64
No anxiolytic
Daily hypnotic 1.08 0.301 0.93 1.25
PRN hypnotic 1.77 0.000 1.31 2.40
No hypnotic
Table 2. 
Fixed effect odds ratios including daily, PRN and No psychotropic predictors of mortality within 90 days of the 
final assessment.
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2.2.2 Analysis of time to mortality against prescriptions for psychotropic medications
The purpose of this analysis is to advance findings from the preceding analysis 
in two ways. The first is to replace the binary target variable with a nominal variable 
Figure 1. 
Proportionate mortality by antipsychotic frequency in men and women.
Figure 2. 
Proportionate mortality by antidepressant frequency in men and women.
Figure 3. 
Proportionate mortality by analgesic frequency in men and women.
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Figure 4. 
Proportionate mortality by anxiolytic frequency in men and women.
Figure 5. 
Proportionate mortality by hypnotic frequency in men and women.
of time to death. The categories are 1–7, 8–30 and 31–90 days after the final assess-
ment. We chose these categories to index mortality shortly, soon, and sometime 
after the final assessment but before the next scheduled assessment. The reference 
category is no recorded death. This analysis allows to use examine relationships 
between mortality and psychotropic prescriptions using a finer temporal scale.
The second advance is to include the CHESS scale [10] as a fixed effect. The 
CHESS is arguably the strongest current predictor of mortality for people within 
continuing care contexts. For example, mortality in the present database is <10% 
for residents with the lowest score but >85% for residents with the highest score. 
Consequently, inclusion of the CHESS helps us to test between two interpreta-
tions of PRN/mortality relationships. On the one hand, if nearness of death is 
the primary reason for PRN prescription (i.e., prescribed mainly for palliative 
reasons), its relationship to mortality should nullify after inclusion of the CHESS 
as a fixed effect. On the other hand, if PRN prescription increases the risk of 
subsequent mortality, a relationship should endure despite inclusion of the 
CHESS as a fixed effect.
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The target variable in this analysis has a multinomial distribution with a gen-
eralized logit link. The random and fixed effects are the same as in the preceding 
analysis except for the addition of the CHESS as a fixed effect. The fixed effect 
coefficients for this analysis comprise a multi-layered table, wherein each layer 
represents a different time to death category. However, we present each layer as a 
separate table in order to improve ease of readability.
Tables 3–5 respectively show findings from 1–7, 8–30, 31–90 days from the final 
assessment. The findings for demographic, functional capability and mortality risk 
measures show the following trends. Over all three mortality intervals, mortality is 
lower in women than men, higher at older ages, higher with greater activity limita-
tion and higher with higher CHESS scores. For the interval 8–30 days after the final 
assessment, mortality is lower with higher cognitive impairment (i.e., higher scores 
on the scale).
Compared to a reference category of no medication, the findings for prescribed 
medications show the following. Table 3 shows mortality 1–7 days from the final 
assessment to be significantly lower with daily antidepressant prescription but signifi-
cantly higher with PRN prescription of antipsychotics, analgesics and antidepressants.
Table 4 shows mortality 8–30 days after the final assessment is significantly 
lower with daily antidepressant and daily analgesic prescriptions but significantly 
higher with PRN anxiolytics and PRN analgesic prescriptions.
Model term Odds ratio Sig. 95% confidence interval
Lower Upper
Intercept 0.017 0.000 0.013 0.022
Female 0.533 0.000 0.432 0.659
Male
Age at assessment 1.032 0.000 1.017 1.048
Activities of daily living 1.625 0.000 1.484 1.780
Cognitive performance 0.986 1.000 0.922 1.053
CHESS scale 2.489 0.000 2.294 2.700
Daily antipsychotic 0.859 0.222 0.670 1.102
PRN antipsychotic 2.139 0.009 1.273 3.594
No antipsychotic
Daily antidepressant 0.606 0.000 0.487 0.755
PRN antidepressant 1.696 0.045 1.010 2.847
No antidepressant
Daily analgesic 1.104 0.395 0.863 1.410
PRN analgesic 2.655 0.000 1.916 3.681
No analgesic
Daily anxiolytic 0.997 0.903 0.716 1.388
PRN anxiolytic 1.006 0.942 0.617 1.640
No anxiolytic
Daily hypnotic 1.104 0.586 0.711 1.716
PRN hypnotic 1.592 0.318 0.666 3.806
No hypnotic
Table 3. 
Fixed effect odds ratios for predictors of mortality within 7 days after the final assessment.
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During the 31–90 day interval after the final assessment, Table 5 shows 
significantly lower mortality with daily antidepressant prescription but 
significantly higher mortality with PRN analgesic, anxiolytic, and hypnotic 
prescriptions.
At one or more levels of the target variable, the findings from this analysis repli-
cate those from the preceding analysis that relate male gender, older age and greater 
activity limitation to significantly augmented mortality. They also replicate find-
ings of augmented mortality with PRN prescription for all types of psychotropic 
medication. They further extend relationships of attenuated mortality to include 
daily prescription of both analgesic and antidepressant medication. The only failure 
of replication is the absence of significantly attenuated mortality with daily pre-
scription of antipsychotic medication, despite a coefficient close to significance for 
the 8–30 day interval. Other significant findings include attenuated mortality with 
cognitive impairment (i.e., higher scores on the scale) at the 8–30 day interval and 
augmented mortality at each level of the target variable with higher estimates of 
mortality risk on the CHESS.
The inclusion of the CHESS provides a rationale to interpret findings of attenu-
ated or augmented mortality associated with psychotropic prescriptions. The pres-
ence of such findings after control for the CHESS supports an interpretation that 
Model term Odds ratio Sig. 95% confidence interval
Lower Upper
Intercept 0.089 0.000 0.077 0.103
Female 0.596 0.000 0.525 0.677
Male
Age at assessment 1.022 0.000 1.013 1.031
Activities of daily living 1.495 0.000 1.423 1.572
Cognitive performance 0.947 0.047 0.909 0.986
CHESS scale 1.883 0.000 1.786 1.986
Daily antipsychotic 0.881 0.084 0.761 1.020
PRN antipsychotic 1.335 0.280 0.872 2.043
No antipsychotic
Daily antidepressant 0.675 0.000 0.594 0.768
PRN antidepressant 1.152 0.497 0.758 1.753
No antidepressant
Daily analgesic 0.824 0.007 0.719 0.943
PRN analgesic 1.574 0.000 1.274 1.946
No analgesic
Daily anxiolytic 0.885 0.337 0.721 1.086
PRN anxiolytic 1.482 0.006 1.113 1.974
No anxiolytic
Daily hypnotic 1.049 0.624 0.802 1.370
PRN hypnotic 1.585 0.148 0.872 2.880
No hypnotic
Table 4. 
Fixed effect odds ratios for predictors of mortality 8–30 days after the final assessment.
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the medicinal prescriptions have direct or indirect effects on mortality beyond the 
levels of risk measured by the tool. An alternative interpretation that the findings 
on mortality are secondary to altered prescribing practices with perceived closeness 
to death seems less plausible.
2.2.3 Analysis of predictors of multiple daily and PRN psychotropic prescriptions
LTCH residents may receive more than a single type of psychotropic medication 
on a daily or PRN basis. The purpose of these analyses is to identify variables that 
contribute to the number of such prescriptions. The target variable in both analyses 
is the number of psychotropic categories prescribed on a daily or PRN basis. We 
modeled the target as an ordinal measure with a cumulative logit link in mixed 
multinomial logistic regression models. Levels on the daily prescription distribution 
are 0, 1, 2, 3 and 4+ ordinal categories. Levels on the PRN prescription distribution 
are 0, 1, 2 and 3+ ordinal categories.
The fixed effects include the same demographic, functional capability and mortality 
risk measures as in the preceding analyses. Other measures are scales (i.e., Depression, 
Aggressive Behavior, and Pain scales), diagnoses (i.e., Anxiety Disorder, and Dementia) 
and conditions (i.e., Insomnia) that might influence psychotropic medication use. We 
added a final fixed effect of the total number of prescribed medications.
Model term Odds ratio Sig. 95% confidence interval
Lower Upper
Intercept 0.140 0.000 0.124 0.158
Female 0.650 0.000 0.587 0.720
Male
Age at assessment 1.039 0.000 1.031 1.046
Activities of daily living 1.326 0.000 1.277 1.377
Cognitive performance 0.986 0.901 0.953 1.020
CHESS scale 1.542 0.000 1.474 1.614
Daily antipsychotic 0.989 0.807 0.882 1.108
PRN antipsychotic 1.436 0.092 1.003 2.056
No antipsychotic
Daily antidepressant 0.822 0.000 0.743 0.909
PRN antidepressant 1.226 0.269 0.854 1.758
No antidepressant
Daily analgesic 0.894 0.052 0.803 0.995
PRN analgesic 1.406 0.000 1.172 1.687
No analgesic
Daily anxiolytic 1.011 0.689 0.866 1.181
PRN anxiolytic 1.392 0.006 1.093 1.772
No anxiolytic
Daily hypnotic 1.080 0.376 0.875 1.333
PRN hypnotic 1.990 0.006 1.243 3.186
No hypnotic
Table 5. 
Fixed effect odds ratios for predictors of mortality 31–90 days after the final assessment.
Aging - Life Span and Life Expectancy
14
The findings in Table 6 show fixed findings for daily prescriptions of psy-
chotropic medication. The table includes thresholds (i.e., intercepts) at differ-
ent levels of the target variable and coefficients for the predictors. Predictors 
of significantly higher frequencies of daily prescription include categorical 
measures of female gender, anxiety disorder, insomnia, and dementia; higher 
scores on scales measuring activity limitation, cognitive impairment, depres-
sion, aggressive behavior, and pain; and the total number of medications. These 
findings suggest that residents prescribed more types of psychotropic medication 
have higher levels on multiple conditions that might benefit from psychotropic 
intervention. Findings that seem at odds with the preceding are relationships of 
younger age and lower mortality risk (i.e., on the CHESS) to higher frequencies 
of daily psychotropic prescriptions.
Table 7 shows fixed effect findings for PRN prescriptions of psychotropic medi-
cation. Significant predictors of higher levels of PRN prescribing are limited to the 
Aggressive Behavior, Pain, and CHESS scales, and the presence of insomnia. Age and 
diagnosed dementia have negative relationships with the number of PRN prescriptions.
The most revealing differences in outcome of the two preceding analyses relate 
to diagnosed dementia and the CHESS scale. Diagnosed dementia relates posi-
tively to the number of daily but negatively to the number of PRN prescriptions. 
Conversely, higher mortality risk relates negatively to the number of daily but 
positively to the number of PRN prescriptions.
Model term Odds ratio Sig. 95% confidence interval
Lower Upper
Threshold for Number = 0 0.225 0.000 0.214 0.237
Threshold for Number = 1 1.504 0.000 1.433 1.579
Threshold for Number = 2 9.442 0.000 8.970 9.939
Threshold for Number = 3 87.211 0.000 81.593 93.216
Female 1.047 0.002 1.017 1.079
Male
Age at assessment 0.973 0.000 0.971 0.974
Activities of daily living 1.015 0.003 1.005 1.025
Cognitive performance 1.118 0.000 1.105 1.131
Depression scale 1.108 0.000 1.100 1.115
Aggressive behavior scale 1.067 0.000 1.060 1.074
Pain scale 1.208 0.000 1.187 1.230
CHESS scale 0.915 0.000 0.900 0.929
Anxiety disorder 2.744 0.000 2.599 2.896
No anxiety disorder
Insomnia 1.124 0.000 1.079 1.170
No insomnia
Dementia 1.393 0.000 1.348 1.439
No dementia
Total medications 1.191 0.000 1.187 1.195
Table 6. 
Fixed effect odds ratios for predictors of number of daily medications for the final assessment.
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2.2.4 Analysis of mortality against multiple daily and PRN psychotropic prescriptions
The purpose of this analysis is to ascertain relationships between mortality 
within 90 days of the final assessment and the distribution of prescriptions of 
psychotropic medications at the final assessment. The target variable has a binomial 
distribution with a complementary log-log link. The fixed effect variables include 
the same demographic, functional capability and mortality risk measures as previ-
ous analyses. Categories within the distribution of prescriptions include (1) no 
prescriptions, (2) daily and PRN prescriptions, (3) PRN prescriptions only and (4) 
daily prescriptions only. The reference category is zero prescriptions.
The findings in Table 8 show significantly lower mortality for women than 
men and for residents with greater cognitive impairment (i.e., lower scores on the 
scale). Mortality is significantly higher at older ages and for residents scoring higher 
on activity limitation and the CHESS measure of mortality risk. Findings for the 
distribution of prescriptions show significantly attenuated mortality for residents 
with daily prescriptions only, significantly augmented mortality residents with 
PRN prescriptions only, and significantly augmented mortality for residents with 
both daily and PRN prescriptions. Paired comparisons with Bonferroni correction 
show significant differences across all four categories.
We interpret these findings as follows. Antipsychotics, antidepressants and anal-
gesics have the highest rates of daily prescription. Daily prescription of each of those 
psychotropics attenuates mortality in at least one of our analyses. Consequently, the 
present association between attenuated 90-day mortality in residents with only daily 
prescriptions is unsurprising. For similar reasons, findings of augmented mortality in 
Model term Odds ratio Sig. 95% confidence interval
Lower Upper
Threshold for Number = 0 7.737 0.000 6.970 8.587
Threshold for Number = 1 73.344 0.000 63.257 85.040
Threshold for Number = 2 399.408 0.000 303.212 526.123
Female 1.033 0.496 0.941 1.134
Male
Age at assessment 0.993 0.029 0.988 0.999
Activities of daily living 1.019 0.252 0.987 1.052
Cognitive performance 0.977 0.194 0.942 1.012
Depression scale 1.008 0.437 0.988 1.028
Aggressive behavior scale 1.085 0.000 1.064 1.107
Pain scale 1.334 0.000 1.268 1.404
CHESS scale 1.214 0.000 1.165 1.266
Anxiety disorder 0.991 0.917 0.838 1.173
No anxiety disorder
Insomnia 1.618 0.000 1.444 1.812
No insomnia
Dementia 0.789 0.000 0.710 0.877
No dementia
Total medications 0.996 0.423 0.986 1.006
Table 7. 
Fixed effect odds ratios for predictors of number of PRN medications for the final assessment.
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residents with only PRN prescriptions are also unsurprising. The new ground break-
ing findings, however, concern residents with both daily and PRN prescriptions. This 
combination significantly augments mortality from levels that typify daily prescrip-
tion and no prescription, but significantly attenuates levels that typify only PRN 
prescriptions. Figure 6 shows that the respective mortality levels are independent of 
mortality risk, as estimated by categories of CHESS scores. Consequently, we infer 
that PRN prescription may overturn protective effects associated with daily prescrip-
tions, whereas the latter may reduce the deleterious effects of PRN prescribing.
2.2.5 Additional analyses
Because of the statistical significance of LTCH as a random effect in all the 
preceding analyses, we report here on additional analyses that explore whether 
Model term Odds ratio Sig. 95% confidence interval
Lower Upper
Intercept 0.21 0.000 0.19 0.23
Female 0.67 0.000 0.63 0.72
Male
Age at assessment 1.03 0.000 1.02 1.03
Activities of daily living 1.36 0.000 1.32 1.40
Cognitive performance 0.97 0.007 0.95 0.99
CHESS scale 1.58 0.000 1.53 1.62
Only daily prescriptions 0.76 0.000 0.69 0.84
Only PRN prescriptions 1.42 0.000 1.21 1.66
Daily and PRN prescriptions 1.17 0.025 1.02 1.34
No prescriptions
Table 8. 
Fixed effect odds ratios for mortality within 90 days of the final assessment.
Figure 6. 
Proportionate mortality by prescription regimens and CHESS categories.
17
Psychotropic Medication Use and Mortality in Long-Term Care Residents
DOI: http://dx.doi.org/10.5772/intechopen.85971
particular differences among LTCH contribute to fixed effect relationships to 
mortality. Specifically, the analyses include facility-level covariates that correspond 
with previously significant, resident-level fixed effect terms. These centered facility-
level covariates are LTCH means for age, level of activity limitation, and mortality 
risk (i.e., CHESS scores); and percentages of residents by gender and psychotropic 
prescription on a PRN basis. The findings indicate that these facility-level variables 
have significant zero-order relationships with mortality in the same directions as the 
corresponding resident-level measure. However, all are nonsignificant when added 
to the list of fixed effects described in the preceding section (i.e., Section 2.2.4), 
with the odds-ratios and significance levels for resident-level terms showing mini-
mal change from those in Table 8. We conclude, therefore, that the findings with 
resident-level fixed effects show negligible influence due to distributions in LTCH.
2.3 Discussion
This chapter charts a journey of scientific investigation with the following 
milestones:
1. Concern about excess mortality with the use of antipsychotic medication.
2. Findings that limit the preceding relationship to PRN prescription.
3. Findings that excess mortality with PRN prescription applies to all types of 
psychotropic medication.
4. Findings of attenuated mortality with daily prescription for some types of 
psychotropic medication but augmented mortality with PRN prescription for 
all types of medication.
5. Evidence to support the preceding after control for confounders that include a 
proven indicator of mortality risk.
6. Findings that diagnosed dementia relates positively to the number of daily but 
negatively to the number of PRN prescriptions, whereas higher mortality risk 
relates negatively to the number of daily but positively to the number of PRN 
prescriptions.
7. Evidence that a combination of daily and PRN prescriptions of psychotropics 
overturns protective effects against mortality associated with the former but 
lowers deleterious effects associated with PRN prescribing.
The journey began with concern about excess mortality with the use of 
antipsychotic medication but ends with evidence for minor protective effects of 
daily prescription. How do we account for this discrepancy? Consider, first, the 
quality of measurement and, second, the appropriateness of the analyses. We 
have confidence in the data quality and psychometric adequacy (i.e., reliability 
and validity) of the RAI 2.0 measures. For nearly 30 years, efforts by research-
ers from across the world tried to ensure good measurement quality. A recent 
example is research on 15 years of archived data in Canada. Those authors report 
favorable outcomes, concluding that the RAI 2.0 provides a “robust, high qual-
ity data source” ([28], p. 27). If our data possess unrecognized error in measure-
ment, similar error likely contaminates findings from many hundred referred 
publications that rely on RAI 2.0 data.
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Second, we consider the technical details of our methodology to be appropriate. 
The decision to restrict analysis to data from new admissions ensures that the findings 
from over 20,000 residents provide 1-year incidence rates (rather than prevalence 
rates) for mortality. Such restriction also ensures that the data from all residents begin 
with comparable intake assessments. Earlier in this chapter, we provide conceptual 
reasons to justify the appropriateness of GLMM analysis. In every analysis, findings 
of significant random effects for LTCH provide empirical justification. Our wish for 
the future is that more researchers adopt similar modeling in order to avoid incorrect 
assumptions that measurement error is uncorrelated in clustered data.
We also ought to mention here that the statistical models show reasonable data 
fit in every analysis. The final model in Table 8 provides an example. Compared to a 
simplified model that includes only demographics as fixed effects, the proportions of 
correct classification in the full model improve by 16.3% for predicted mortality (i.e., 
from 50 to 66.3%) and by 2.4% for the prediction of nonmortality (i.e., from 82.1 to 
84.5%). These gains are fairly impressive given the lopsided skew in mortality data.
We conclude from the preceding is that our findings are trustworthy. How then 
can we account for findings from other studies of excessive mortality among elderly 
people prescribed with antipsychotic medication? We offer three possible interpre-
tations. The first is a failure by many or most such studies to distinguish between 
daily and PRN prescribing. The second is a failure to provide information about 
PRN prescription of other psychotropic medications. Because our findings suggest 
associations between augmented mortality and PRN prescription of any psychotro-
pic, each of the preceding concerns anticipates overestimation of mortality.
The third interpretation relates to adherence. Anyone with work experience in LTCH 
settings knows that adherence to drug regimens is problematic. Residents that put pills 
into their mouths do not necessarily swallow them. Instead, some residents chose to hide 
their pills, others throw them away. Previous findings show that nonadherence to anti-
depressant medication has unfavorable implications for mortality [19]. Findings from 
psychiatry show frequent low adherence to antipsychotic medication [29]. That study 
reports rates of nonadherence to antipsychotic medication by psychiatric patients as high 
as 40% within a year. Because low adherence results in intermittent use of antipsychotic 
medication, the consequences in LTCH residents could well include excessive mortality.
Our scientific journey progressed past milestones that indicate consistency in 
findings with alternative indices of mortality and control of confounding variables. 
At the end of the journey, the metaphorical villain is no longer daily prescription of 
psychotropic medication but PRN prescription. Although relatively few residents 
receive PRN prescriptions on a per drug basis, one resident in eight (12.5%) has at 
least one such prescription. Although residents prescribed PRN medication have 
high mortality risk, as measured by the CHESS, Figure 6 shows elevated mortality 
rates at every level of mortality risk.
Issues that arise from our research include reasons for the high mortality associ-
ated with PRN prescriptions and implications for health care practice and policy. 
However, before such discussion, here are some words of caution.
The present research design is correlational rather that experimental. Only 
the latter assigns individuals randomly to the various conditions. Despite agree-
ment that correlational designs provide less-compelling evidence about causality 
than experimental designs, the majority of studies on the effects of psychotropic 
medications are correlational. For example, most recent studies of the effects 
of antipsychotic medication on mortality have correlation designs that compare 
residents prescribed a given drug with residents without prescription or prescribed 
an alternative medication [6]. However, even in experimental studies, which are 
invariably of short duration [5], any differences in mortality between conditions do 
not necessarily imply direct causation. Such effects may arise because of changes 
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to health stability or changes in likelihood of adverse health events. We make these 
points to warn against simplistic interpretation of complex phenomena.
Efforts within epidemiology to facilitate appropriate causal inferences include pro-
cedures to identify confounding by indication, which “refers to a situation where patient 
characteristics, rather than the intervention, are independent predictors of outcome” 
([30], p. 841). The present analyses encompass procedures used to evaluate confound-
ing by indication, which include, but are not limited to, the following. Covariate 
adjustment in which potential confounders are added to the list of fixed effects in 
modeling (e.g., age, gender, and functional measures). “Propensity” scores were used, 
which relate to the likelihood of intervention (e.g., high CHESS scores increase the 
likelihood of PRN prescription). The use of instrumental variables presumed to sub-
stitute for unmeasured confounders (e.g., LTCH and properties of LTCH as random 
and fixed effect variables, respectively). Although other research reports differences in 
causal direction depending on the kind of analysis [30], the present findings indicate 
directional consistency in relationships between mortality and PRN prescribing before 
(Figures 1–5) and after adjustment of variables from all three classes of confound.
However, our analyses clearly omit control for unmeasured sources of confound-
ing. Also, our research lacks the rigor that random assignment brings to experimen-
tal forms of design. Consequently, we strongly recommend that future randomized 
controlled trials evaluate the relationships we report here.
Our cautious interpretation of effects on mortality associated with daily and PRN 
prescription of psychotropic medication rests heavily on findings from the final analysis. 
These findings indicate that PRN prescription overturns any protective effects associated 
with daily prescription, whereas daily prescription lowers adverse consequences of PRN 
prescribing. These findings suggest a mutually antagonistic relationship between daily 
and PRN prescriptions with respect to their effects on mortality. The clinical rationale 
for daily prescription is the alleviation of disturbance to a resident’s equilibrium, as 
exemplified by aggression, depression, pain, anxiety and insomnia. Successful treat-
ment results in regained equilibrium after the resident adapts to regular ingestion of the 
drug. Conversely, the reasoning behind PRN prescription is to alleviate disturbances to 
equilibrium thought to be temporary. However, irregularity of ingestion is antagonistic 
to adaptation and may exacerbate instability through toxicity rather than help restore 
equilibrium. This interpretation appears to be consistent with our findings. Practical 
implications for health care practices and policy are consistent with current trends. Such 
trends include the de-prescribing of psychotropic medications for older people, with 
such medications to be used only for short durations and as a last resort [5, 6]. Similarly, 
a recent rewrite of Medicaid Long Term Care rules in the USA states that LTCH residents 
must not be prescribed antipsychotic, antidepressant, anxiolytic or hypnotic medica-
tions unless necessary to treat a specific condition diagnosed and documented in the 
clinical record. The new rules also normally limit PRN prescriptions to 14 days. Any 
extension requires an attending physician or prescribing practitioner to document the 
rationale in the resident’s medical record [31]. We especially applaud these latter rules, 
which tackle an issue hitherto neglected in health care practice and policy.
3. Conclusion
PRN prescriptions of psychotropic medications have more aversive effects on 
the mortality of LTCH residents than daily prescriptions. These findings apply to 
all types of psychotropic medication after control for major confounding variables. 
The findings also suggest that daily prescription may ameliorate effects on mortality 
associated the PRN prescriptions, whereas PRN prescriptions exacerbate effects on 
mortality associated with daily prescription.
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